Ovid Therapeutics (NASDAQ:OVID – Get Free Report) and Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY – Get Free Report) are both healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their analyst recommendations, profitability, risk, valuation, earnings, institutional ownership and dividends.
Institutional & Insider Ownership
72.2% of Ovid Therapeutics shares are owned by institutional investors. Comparatively, 1.9% of Shionogi & Co., Ltd. Unsponsored ADR shares are owned by institutional investors. 7.0% of Ovid Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Analyst Recommendations
This is a summary of current ratings and recommmendations for Ovid Therapeutics and Shionogi & Co., Ltd. Unsponsored ADR, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Ovid Therapeutics | 1 | 0 | 11 | 0 | 2.83 |
| Shionogi & Co., Ltd. Unsponsored ADR | 0 | 0 | 0 | 3 | 4.00 |
Ovid Therapeutics presently has a consensus price target of $6.12, suggesting a potential upside of 171.62%. Given Ovid Therapeutics’ higher possible upside, equities research analysts clearly believe Ovid Therapeutics is more favorable than Shionogi & Co., Ltd. Unsponsored ADR.
Risk & Volatility
Ovid Therapeutics has a beta of 0.24, suggesting that its share price is 76% less volatile than the S&P 500. Comparatively, Shionogi & Co., Ltd. Unsponsored ADR has a beta of 0.1, suggesting that its share price is 90% less volatile than the S&P 500.
Valuation & Earnings
This table compares Ovid Therapeutics and Shionogi & Co., Ltd. Unsponsored ADR”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Ovid Therapeutics | $7.25 million | 58.70 | -$17.41 million | ($0.24) | -9.40 |
| Shionogi & Co., Ltd. Unsponsored ADR | $3.32 billion | 5.03 | $1.35 billion | $0.90 | 10.90 |
Shionogi & Co., Ltd. Unsponsored ADR has higher revenue and earnings than Ovid Therapeutics. Ovid Therapeutics is trading at a lower price-to-earnings ratio than Shionogi & Co., Ltd. Unsponsored ADR, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares Ovid Therapeutics and Shionogi & Co., Ltd. Unsponsored ADR’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Ovid Therapeutics | N/A | -23.38% | -20.76% |
| Shionogi & Co., Ltd. Unsponsored ADR | 37.95% | 14.32% | 10.24% |
Summary
Shionogi & Co., Ltd. Unsponsored ADR beats Ovid Therapeutics on 9 of the 15 factors compared between the two stocks.
About Ovid Therapeutics
Ovid Therapeutics Inc. is a biopharmaceutical company focused on developing medicines for epilepsies and other neurological disorders. Its work targets conditions with significant unmet treatment needs, including rare and difficult-to-treat seizure disorders. The company’s lead development program, OV329, is an investigational GABA aminotransferase inhibitor being studied as a potential treatment for seizures, including infantile spasms and focal-onset seizures. Ovid’s pipeline and research programs may change as clinical development progresses.
About Shionogi & Co., Ltd. Unsponsored ADR
Shionogi & Co., Ltd. is a Japan-based pharmaceutical company that researches, develops, manufactures and markets prescription medicines. Founded in Osaka in 1878, it has grown from a pharmaceutical wholesaler into a research-focused drugmaker. The company has a particular focus on infectious diseases, including HIV, influenza and COVID-19, and also works in areas such as pain and central nervous system disorders. Its products include Xofluza, an influenza treatment, and ensitrelvir, an oral COVID-19 antiviral marketed in Japan as Xocova.
Receive News & Ratings for Ovid Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ovid Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
